Nom du produit:Diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

IUPAC Name:2,4-diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

CAS:2436-79-5
Formule moléculaire:C12H17NO4
Pureté:95%+
Numéro de catalogue:CM197337
Poids moléculaire:239.27

Unité d'emballage Stock disponible Prix($) Quantité
CM197337-100g in stock ƄŢƄ
CM197337-500g in stock ǯŔŢ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2436-79-5
Formule moléculaire:C12H17NO4
Point de fusion:-
Code SMILES:O=C(C1=C(C)C(C(OCC)=O)=C(C)N1)OCC
Densité:
Numéro de catalogue:CM197337
Poids moléculaire:239.27
Point d'ébullition:372.3°C at 760 mmHg
N° Mdl:MFCD00005218
Stockage:Store at room temperature.

Category Infos

Pyrroles
Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
Pyrrole,Where to Buy Pyrroles-Chemenu
Pyrrole,Where to Buy Pyrroles
Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

Column Infos

Vorolanib
EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.

Related Products